Wednesday, December 4 | 9:50 a.m.-10:00 a.m. | W3-SSBR08-5 | Room S406A
Audience members will learn about how ultrasound shear-wave dispersion (SWD) technology can help measure breast lesion size, depth, and breast thickness.
Bo Kyoung Seo, MD, PhD, from Ansan Hospital in South Korea will discuss findings showing how SWD can boost diagnostic performance for distinguishing between benign and malignant breast masses compared to shear-wave elastography (SWE) across various lesion sizes, depths, and breast thicknesses.
SWE is common for quantifying tissue elasticity, but the researchers noted that its accuracy can be affected by lesion size, depth, and breast thickness.
One recent advancement in this area is the automatic quantification of viscosity through the shear-wave dispersion slope in SWE. The researchers studied the diagnostic performance of SWD in distinguishing between benign and malignant breast masses and explored its supplementary role.
The study included a retrospective dataset of 606 consecutive women scheduled for ultrasound-guided biopsy. The team performed SWD and SWE before biopsy. In total, it included 630 breast masses in the study.
For each mass, the researchers measured the average tumor elasticity and tumor-to-fat elasticity ratio using SWE, as well as the average tumor dispersion and tumor-to-fat dispersion ratio using SWD. Of the total masses, 395 were benign and 235 were malignant.
SWD performed significantly better than SWE in the study. These included area under the curve (AUC) values of 0.96 and 0.95 for average tumor dispersion and tumor-to-fat dispersion ratio, respectively. SWE achieved AUC values of 0.93 and 0.93 for average tumor elasticity and tumor-to-fat elasticity ratio, respectively (p < 0.05 for all).
And in small masses (≤ 10 mm), average tumor dispersion achieved a sensitivity of 70%, a positive predictive value (PPV) of 85%, and a specificity of 98%. Also, average tumor dispersion achieved the highest sensitivity and specificity in lesions of any depth and breast thickness.
So how does this all compare to SWE and what could it mean for SWD’s potential place in the clinic? Attend this session to find out more.
